IMC Chicago LLC Invests $6.01 Million in BioCryst Pharmaceuticals, Inc. $BCRX

IMC Chicago LLC bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) during the first quarter, Holdings Channel.com reports. The fund bought 631,290 shares of the biotechnology company’s stock, valued at approximately $6,010,000.

Other large investors have also added to or reduced their stakes in the company. RA Capital Management L.P. acquired a new stake in BioCryst Pharmaceuticals during the 4th quarter valued at $123,452,000. Deerfield Management Company L.P. increased its holdings in shares of BioCryst Pharmaceuticals by 159.4% in the third quarter. Deerfield Management Company L.P. now owns 12,169,000 shares of the biotechnology company’s stock valued at $92,363,000 after purchasing an additional 7,477,000 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of BioCryst Pharmaceuticals by 7,807.2% in the fourth quarter. Janus Henderson Group PLC now owns 7,404,386 shares of the biotechnology company’s stock valued at $57,791,000 after purchasing an additional 7,310,745 shares during the period. Perceptive Advisors LLC bought a new position in shares of BioCryst Pharmaceuticals in the fourth quarter valued at about $24,668,000. Finally, RFG Advisory LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter worth about $27,329,000. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $9.41 on Thursday. The stock’s fifty day moving average price is $9.18 and its two-hundred day moving average price is $8.49. BioCryst Pharmaceuticals, Inc. has a one year low of $6.00 and a one year high of $11.22. The firm has a market cap of $2.39 billion, a PE ratio of -5.29 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). The company had revenue of $156.41 million for the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business’s revenue was up 7.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.20 earnings per share. Sell-side analysts expect that BioCryst Pharmaceuticals, Inc. will post -2.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts recently commented on BCRX shares. Needham & Company LLC reduced their target price on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday, May 6th. Cantor Fitzgerald increased their price target on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a report on Tuesday, June 30th. Weiss Ratings restated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research report on Monday, June 1st. Royal Bank Of Canada boosted their price objective on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Wall Street Zen downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 9th. Eight equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $20.80.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.